ArticleBiotechnology and bioengineering2012
Different expression systems for production of recombinant proteins in Saccharomyces cerevisiae.
Article in Biotechnology and bioengineering, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed.
- Truncation ofSynthetic and systems biotechnology · 2026Article
- Purification-free antifungal biocontrol platform using engineered Saccharomyces cerevisiae secreting Trichoderma atroviride chitinase.Bioresources and bioprocessing · 2026Article
- Biofilm-based continuous secretion of human lysozyme through cell-surface display of FimH onSynthetic and systems biotechnology · 2026Article
- Review of Xylanases: Sources, Engineering and Biotechnological Use.Microorganisms · 2026Review
- Recombinant collagen in regenerative medicine: Expression strategies, structural design, and translational applications.Materials today. Bio · 2025Review
- YTK Display-and-Secrete: Screening for Optimal Protein Secretion Elements inACS synthetic biology · 2025Article
- Raman-Enabled Predictions of Protein Content and Metabolites in BiopharmaceuticalEngineering in life sciences · 2024Article
- AMWEst, a new thermostable and detergent-tolerant esterase retrieved from the Albian aquifer.Applied microbiology and biotechnology · 2024Article
- Penetrating the ultra-tough yeast cell wall with finite element analysis model-aided design of microtools.iScience · 2024Article
- Heterologous Production of Antimicrobial Peptides: Notes to Consider.The protein journal · 2024Article
- EngineeringEngineering microbiology · 2024Review
- Review
- Construction of recombinant Lactococcus expressing thymosin and interferon fusion protein and its application as an immune adjuvant.Microbial cell factories · 2024Article
- Copper-Induced In Vivo Gene Amplification in Budding Yeast.Biodesign research · 2024Article
- Cold Exposure and Oral Delivery of GLP-1R Agonists by an Engineered Probiotic Yeast Strain Have Antiobesity Effects in Mice.ACS synthetic biology · 2023Article
- Functions and substrate selectivity of diacylglycerol acyltransferases from Mortierella alpina.Applied microbiology and biotechnology · 2023Article
- Engineering Saccharomyces cerevisiae for improved biofilm formation and ethanol production in continuous fermentation.Biotechnology for biofuels and bioproducts · 2023Article
- Study of the regulatory elements of the Ovalbumin gene promoter using CRISPR technology in chicken cells.Journal of biological engineering · 2023Article
- Improving therapeutic protein secretion in the probiotic yeast Saccharomyces boulardii using a multifactorial engineering approach.Microbial cell factories · 2023Article
- Maximizing protein production by keeping cells at optimal secretory stress levels using real-time control approaches.Nature communications · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Yeast Saccharomyces cerevisiae has become an attractive cell factory for production of commodity and speciality chemicals and proteins, such as industrial enzymes and pharmaceutical proteins. Here we evaluate most important expression factors for recombinant protein secretion: we chose two different proteins (insulin precursor (IP) and α-amylase), two different expression vectors (POTud plasmid and CPOTud plasmid) and two kinds of leader sequences (the glycosylated alpha factor leader and a synthetic leader with no glycosylation sites). We used IP and α-amylase as representatives of a simple protein and a multi-domain protein, as well as a non-glycosylated protein and a glycosylated protein, respectively. The genes coding for the two recombinant proteins were fused independently with two different leader sequences and were expressed using two different plasmid systems, resulting in eight different strains that were evaluated by batch fermentations. The secretion level (µmol/L) of IP was found to be higher than that of α-amylase for all expression systems and we also found larger variation in IP production for the different vectors. We also found that there is a change in protein production kinetics during the diauxic shift, that is, the IP was produced at higher rate during the glucose uptake phase, whereas amylase was produced at a higher rate in the ethanol uptake phase. For comparison, we also refer to data from another study, (Tyo et al. submitted) in which we used the p426GPD plasmid (standard vector using URA3 as marker gene and pGPD1 as expression promoter). For the IP there is more than 10-fold higher protein production with the CPOTud vector compared with the standard URA3-based vector, and this vector system therefore represent a valuable resource for future studies and optimization of recombinant protein production in yeast.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.